PitchBook’s Post

We are rolling into #JPM2024! 🚚 With all the pharma and healthcare leaders converging on San Francisco, it’s hard not to feel energized for the year ahead. One recurring theme from the past few days? The convergence of science and tech. Technology is the “new competitive frontier” — and many agree, will be a key driver of future success. That’s why we’re proud to help #biotech and #pharma lead with high quality data. Want a deeper dive? Here’s what experts are saying about the current state of tech in biopharma: https://lnkd.in/eypGfHPi

Navigating intricate technologies, adapting to ever-changing regulatory landscapes, managing impending patent expirations, and adjusting to post-pandemic market dynamics are just a few of the multifaceted challenges that Life Science sales professionals confront. While the future outlook is promising, biotech organizations must elevate their strategies to outpace fierce competition and establish distinctiveness. Here at Mercuri, we help our clients in the Life Sciences space with training programs across a vast range of modalities, supporting these organizations in building their teams and capabilities to mirror the rapidly evolving global landscape. Learn more @ https://us.mercuri.net/ #strategy #economy #sales #salesexecutive #salestraining #pharma #lifesciences #biotech

Struggling to keep up with pending biotech approvals? I've got you covered! I've seen the excitement building for this year's PDUFA dates. With numerous innovative therapies on the horizon, these key regulatory deadlines are more crucial than ever for both companies and patients awaiting new treatments. - Biotech firms are on the edge of their seats, anticipating the FDA's verdict on ground-breaking products. - The ripple effect of these approvals could be substantial, affecting market dynamics, investment trends, and most importantly, patient care. - It's a pivotal period for the industry as we await decisions that could redefine treatment standards across several therapeutic areas. The stakes are high, and the outcomes will shape the sector's future. Let's engage in a meaningful conversation around this. Share your insights on upcoming approvals or ask your burning questions. Feel free to reach out directly for insights on how these developments might influence life sciences talent acquisition and team expansions! #Biotech #PDUFA #LifeSciences

Every year, #Scrip gathers predictions from around 300 #biopharma executives and experts. The resulting “Scrip Asks” series is one of our best-read features, outlining the industry’s view of the coming year in a range of important areas, including financing, deal-making, transformative technology, clinical trial trends, therapeutic area trends, manufacturing and more. #freecontent #CitelineCommercial #financing #transformativetechnology #clinicaltrial

Entering 2024, the life sciences sector embarks on a journey marked by profound transformation and digital advancements. Successfully navigating this terrain demands a combination of foresight and agility, as companies grapple with the dual challenges posed by intricate regulatory frameworks and unpredictable market conditions. Read Artem's article to learn about five main trends we can expect to see in the life sciences industry in 2024. What other Pharma trends should we watch out for? #PharmaIndustry #GlobalTrends #DataInsights #2024 #RealStaffing

The Pharma Manufacturing World Summit by Executive Platforms kicks off today! Over the next three days, key members of #TeamSpark will participate in four insightful sessions covering a spectrum of interesting topics: from industry trends and commercialization complexities to leveraging platform processes and accelerating time to market. If you’re attending #PMWS, make sure to catch these invaluable sessions! #GeneTherapy #LifeSciences

Hello to the life science community attending and showcasing at one of the three major conferences to start off the new year: #JPM2024 in San Francisco, #biotechshowcase, also in San Francisco, and #DUPHAT2024 in Dubai. As we start off a new year of advancements and collaborations, I wish you all engaging and informative discussions and partnering meetings. As you navigate through these events, gathering insights and building alliances, I am excited about the prospect of catching up with my contacts, both old and new, upon your return. Let’s exchange insights into challenges and opportunities. Let PassionBio/.tech support you in executing your new alliances, managing your technical due diligences, and overseeing your Capex projects. We are here to spearhead your market evaluation, expand your client base, build your overseas representation, out-license your drug candidate, or safeguard external manufacturing resources. Getting GMP ready is not just a compliance step; it's a strategic move towards quality, excellence, and capital readiness. Looking forward to touch base post these conferences and exploring how we can turn the new year's trends into your next success story. #LifeSciences #Biotech #Pharma #MedTech #JPM2024 #biotechshowcase #DUPHAT2024 #CapexProjects #GMP #BusinessDevelopment #GlobalExpansion

Last year, a lot of Emerging Biopharma's were talking about transitioning to a commercial stage. NOW is the time for ACTION. Why not start the new year out right by reviewing one of our webinars from last summer that discussed the technology capabilities needed to successfully commercialize? Learn the best practices for commercializing, plus how life sciences organizations could accelerate innovation, by future-proofing their technology investments today. Click on this link to register and then to view:  https://lnkd.in/eqF9_QmR #biopharma #commercialization #futureisnow #iqvia

Hear Susan Nemetz and the Corval team as they discuss the role of technology in creating a paradigm shift in biopharma commercialization planning. The dynamic financial environment brings increased pressures and magnifies familiar pain points for emerging companies, elevating the need for a new approach to help teams get a fast, efficient, and early start on commercialization planning. https://lnkd.in/dwTvY6f7

In the biotech sector, active management may be particularly valuable — that's according to a recent article by The Wall Street Journal featuring Portfolio Manager Andy Acker. Check it out to see why the ability to discern winners from losers can make an outsized impact in the category 👉 https://bit.ly/3vlq1Cr #JHI #JanusHenderson #BrighterFutureTogether #Opinion #Biotech #Healthcare #Biopharma #Equities #Stocks #US Find important information, including objectives, risks, fees, expenses, current performance, and other disclosures including a prospectus: https://bit.ly/48lIltE